Sisätautien yksikkö
Department of Internal Medicine

Julkaisut 2001
Publications 2001

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Böhm J. Prognosis of Differentiated Thyroid Carcinoma. Relation to Clinical Factors and Cell Adhesion.
2 Cohn JN et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
3 Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study.
4 Dickstein K et al. Comparison of baseline data, initial course, and management: Losartan versus Captopril following acute myocardial infarction (The OPTIMAAL Trial).
5 Ebeling F et al. Factors predicting interferon treatment response in patients with chronic hepatitis C: late viral clearance does not preclude a sustained response.
6 Erkkilä AT et al. APOE polymorphism and the hypertriglyceridemic effect of dietary sucrose 1-3.
7 EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries.
8 EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme.
9 Goldstein S et al. Metoprolol controlled release/extended release in patients with severe heart failure: Analysis of the experience in the MERIT-HF Study.
10 Halinen MO. Ikä ja antikoagulanttihoito.
11 Heikkinen M et al. Prevalence of gastric metaplasia in the duodenal buld is low in Helicobacter pylori postive non-ulcer dysplasia patients.
12 Heliö T et al. Laajentavan kardiomyopatian geenivirheet.
13 Häkkinen A et al. Strength training induced adaptations in neuromuscular function of premenopausal women with fibromyalgia: comparison with healthy women.
14 Häkkinen A et al. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis.
15 Jokinen C et al. Microbial etiology of community-acquired pneunomia in the adult population of 4 municipalities in Eastern Finland.
16 Jokinen JJ et al. Pitkäaikaisennuste ja elämänlaatu sepelvaltimoiden ohitusleikkauksen jälkeen.
17 Kareinen A et al. Cardiovascular risk factors associated with insulin resistence cluster in families with early-onset coronary heart disease.
18 Kaukua J et al. Clustering of cardiovascular risk factors in type 2 diabetes mellitus: prognostic significance and tracking.
19 Korhonen S et al. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: A controlled, population-based study.
20 Koukkunen H et al. C-reactive proteins, fibrinogen, interleukin-6 and tumour necrosis factor-alfa in the prognostic classification of unstable angina pectoris.
21 Koukkunen H et al. Ruling out myocardial infarction with Troponin T and creatine kinase MB massa: diagnostic and prognostic aspects.
22 Koukkunen H et al. Differences in the diagnosis of myocardial infarction by troponin T compared with clinical and epidemiologic criteria.
23 Kuusisto J et al. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men.
24 Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention.
25 Laakso M. Insulin resistance and its impact on the approach to therapy of type 2 diabetes.
26 Laakso M. Diabetes and cardiovascular disease.
27 Laakso M. Diabetic macroangiopathy.
28 Laivoranta-Nyman S et al. Differences between female and male patients with familial rheumatoid arthritis.
29 Lindi V et al. Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on lon-term weight change in Finnish non-diabetic subjects.
30 Lumiaho A et al. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1.
31 Lundell L et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.
32 Mussalo H et al. Heart rate variability and its determinants in patients with severe or mild essential hypertension.
33 Myllykangas-Luosujärvi R et al. Reply (to Amyloidosis in a series of 964 Portuguese rheumatoid arthritis patients).
34 Myllykangas-Luosujärvi R et al. Two clusters of different rheumatic diseases in moisture damaged buildings.
35 Myrvold HE et al. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery.
36 Neva MH et al. Mortality associated with cervical spine disorders: a population-based study of 1666 patients with rheumatoid arthritis who died in Finland in 1989.
37 Niemelä M, Peuhkurinen K. Tieteelliseen näyttöön perustuva sydämen vajaatoiminnan lääkehoito.
38 Niskanen L et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen.
39 Nousiainen T et al. Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy.
40 Nousiainen T et al. Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake.
41 Nousiainen T et al. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
42 Paavola P et al. Genetic analysis in Finnish families with inflammatory bowel disease supports linkage to chromosome 3p21.
43 Parkkinen L et al. alpha-Synuclein pathology is highly dependent on the case selection.
44 Penttilä HJ et al. Myocardial preservation during coronary surgery with and without cardiopulmonary bypass.
45 Pihlajamäki J et al. A major gene effect on fasting insulin and insulin sensitivity in familial combined hyperlipidemia.
46 Pihlajamäki J et al. The hormone sensitive lipase gene in familial combined hyperlipidemia and insulin resistance.
47 Pirinen E et al. Mahapantaleikkaus lihavuuden kirurgisena hoitona.
48 Pirskanen M et al. An association between a subset of Finnish late-onset Alzheimer´s disease and alpha2-macroglobulin.
49 Pyörälä K, Klaukka T. Sepelvaltimotauti-, diabetes- ja verenpainepotilaiden lipidilääkkeiden käyttö Suomessa vuosina 1996-99.
50 Pyörälä K et al. Toteutuvatko sepelvaltimotaudin sekundaaripreventiota koskevat suositukset?
51 Ristikankare M et al. The effects of gender and age on the colonoscopic examination.
52 Roponen M et al. Inflammatory mediators in nasal lavage, induced sputum and serum of employees with rheumatic and respiratory disorders.
53 Roponen M et al. Inflammatory mediators in nasal lavage, induced sputum and serum of employees with rheumatic and respiratory disorders.
54 Salomaa V et al. Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events: the FINMONICA MI Register Studt.
55 Sarkkinen R et al. Keski-Suomen keskussairaalassa vuosina 1983-1990 ja 1991-1998 hoidetut myeloomapotilaat.
56 Schreiner PJ et al. Gender differences in recurrent coronary events: The FINMONICA MI register.
57 Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.
58 Simula S. Cardiac Adrenergic Innervation in Coronary Artery Disease - Studies with I123-metaiodobenzylguanidine.
59 Sivenius K et al. Effect of a three-amino acid deletion in the alfa2B-adrenergic receptor gene on long-term body weight change in Finnish non-diabetic and type 2 diabetic subjects.
60 The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigato. Effects of clopidogrel in addition to aspirin in patietns with acute coronary syndromes without st-segment elevation.
61 The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality.
62 The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy of combination reduced fibrinolytic therapy and platelet glucoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
63 Udd M et al. Regular-dose versus high-dose omeprazole in peptic ulcer bleeding.
64 Uusimaa P et al. Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.
65 Vaag A et al. Metabolic impact of a family history of type 2 diabetes. Results from a European multicentre study (EGIR).
66 Valkamo M et al. Alexithymia in patients with coronary heart disease.
67 Valkamo M et al. Depression and associated factors in coronary heart disease.
68 Valkamo M et al. Psychiatric morbidity and the presence and absence of angiographic coronary disease in patients with chest pain.
69 Vanhanen M et al. APOE-epsilon4 is associated with weight loss in women with AD . A population-based study.
70 Vauhkonen I. Early Defects in Glucose Metabolism in Relatives of Patients with Different Phenotypes of Diabetes Mellitus.
71 Viitanen L. Studies on the Genetic Basis of Premature Coronary Heart Disease Using Candidate Gene Approach and Genome-Wide Scanning.
72 Viitanen L et al. Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
73 Viitanen L et al. Apolipoprotein E gene promoter (-219G/T) polymorphism is associated with premature coronary heart disease.
74 Voutilainen-Kaunisto R. Ocular Manifestations in Type 2 Diabetes. Controlled Ten-Year Follow-Up Study.
75 Voutilainen-Kaunisto R et al. Maculopathy and visual acuity in newly diagnosed type 2 diabetic patients and non-diabetic subjects: A 10-year follow-up study.
76 Voutilainen-Kaunisto RM et al. Occurrence and predictors of retinopathy and visual acuity in type 2 diabetic patients and control subjects 10-year follow-up from the diagnosis.
77 Wang H et al. New amino acid substitutions in the IRS-2 gene in Finnish and Chinese subjects with late-onset type 2 diabetes.
78 Wedel H et al. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial.
79 Wilhelmsen L et al. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S): Impact of predicted risk on the benefit of cholesterol-lowering treatment.
80 Wood D et al. Rapid assessment of chest pain: The rationale is clear, but evidence is needed.
81 Ylitalo K et al. Reversible ischemic inhibition of F1F0-ATPase in rat and human myocardium.
82 Ylitalo K et al. Evidence suggesting coronary vasodilation as the principal mechanism in the warm-up phenomenon.
83 Ylitalo K, Peuhkurinen K. Tuumorinekroositekijä alfa ja sydän - voidaanko sydänsairauksia hoitaa sytokiineja neutraloimalla?
84 Ylitalo K, Peuhkurinen K. Clinical relevance of ischemic preconditioning.
85 Ågren JJ et al. Postprandial responses of individual fatty acids in subjects homozygous for the threonine- or alanine-encoding allele in codon 54 of the intestinal fatty acid binding protein 2 gene 1,2.

Sisätautien yksikkö Department of Internal Medicine
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008